FRESENIUS MEDICAL CA

FME
Real-time Estimate Quote. Real-time Estimate  - 07/27 03:34:10 pm
68.28EUR -0.61%
Valuation
Fiscal Period: December 2020 2021
Capitalization1 24 56423 754
Entreprise Value (EV)2 38 30137 300
P/E ratio 17,4x18,3x
Yield 1,94%1,75%
Capitalization / Revenue 1,13x1,11x
EV / Revenue 1,76x1,74x
EV / EBITDA 7,70x8,79x
Price to Book 1,80x1,59x
Nbr of stocks (in thousands) 292 869292 888
Reference price (USD) 83,981,1
Announcement Date 02/23/2021-
Previous period Next period
1 EUR in Million
2 USD in Million
Estimates
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: December 2020 2021
Net sales1 21 71621 435
EBITDA1 4 9734 243
Operating profit (EBIT)1 2 8022 484
Operating Margin 12,9%11,6%
Pre-Tax Profit (EBT)1 2 3552 124
Net income1 1 4161 308
Net margin 6,52%6,10%
EPS2 4,824,44
Dividend per Share2 1,631,42
Announcement Date 02/23/2021-
Previous period Next period
1 USD in Million
2 USD
Finances - Leverage
Fiscal Period: December 2020 2021
Net Debt1 13 73813 546
Net Cash position1 --
Leverage (Debt / EBITDA) 2,76x3,19x
Free Cash Flow1 3 8871 617
ROE (Net Profit / Equities) 11,7%9,87%
Shareholders' equity1 12 07113 251
ROA (Net Profit / Asset) 3,60%3,31%
Assets1 39 28539 545
Book Value Per Share2 46,651,0
Cash Flow per Share2 17,58,75
Capex1 1 2601 330
Capex / Sales 5,80%6,21%
Announcement Date 02/23/2021-
Previous period Next period
1 USD in Million
2 USD
Financial Ratios
Size 2021e 2022e
Capitalization 23 754 M $ -
Entreprise Value (EV) 37 300 M $ 36 759 M $
Valuation 2021e 2022e
P/E ratio (Price / EPS) 18,3x 15,5x
Capitalization / Revenue 1,11x 1,06x
EV / Revenue 1,74x 1,66x
EV / EBITDA 8,79x 8,05x
Yield (DPS / Price) 1,75% 1,94%
Price to book (Price / BVPS) 1,59x 1,48x
Profitability 2021e 2022e
Operating Margin (EBIT / Sales) 11,6% 12,5%
Operating Leverage (Delta EBIT / Delta Sales) -8,77x 2,67x
Net Margin (Net Profit / Revenue) 6,10% 6,81%
ROA (Net Profit / Asset) 3,31% 3,90%
ROE (Net Profit / Equities) 9,87% 10,8%
Rate of Dividend 32,1% 30,0%
Balance Sheet Analysis 2021e 2022e
CAPEX / Sales   6,21% 6,13%
Cash Flow / Sales 12,0% 13,2%
Capital Intensity (Assets / Sales) 1,84x 1,75x
Financial Leverage (Net Debt / EBITDA) 3,19x 2,81x
Price Earning Ratio
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS & Dividend